David Sinclair· PhD
Our OSK therapy extends lifespan of very old mice, suggesting it’s at least not harmful
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Our OSK therapy extends lifespan of very old mice, suggesting it’s at least not harmful
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
In vivo partial #reprogramming by OSKM expression is effective in delaying natural #aging-related molecular and physiological phenotypes
This week Davidsohn and colleagues showed our exact system extends lifespan in very old mice, when initiated at the human equivalent age of 70-80!
Just 2.5 weeks of OSKM reprogramming of young mice 🐁 increased age of death for the third quartile by 17%, with health benefits seen more than 2 years later 😮
Old mice (= human 80) treated with age reprogramming OSK therapy are healthier and longer lived 😯
Our new article reveals that gene therapy-mediated partial reprogramming extends lifespan and reverses age-related changes in aged mice, showcasing lifespan extension in wild-type animals through in vivo reprogramming.
“Here, we show that..an inducible OSK system in 124-week-old mice extends the median remaining lifespan by 109% and enhances several health parameters.”